FY2019 EPS Estimates for Epizyme Inc Reduced by Analyst (EPZM)
Epizyme Inc (NASDAQ:EPZM) – Analysts at SunTrust Banks dropped their FY2019 earnings per share (EPS) estimates for shares of Epizyme in a research note issued to investors on Monday, September 24th. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will earn ($2.30) per share for the year, down from their previous forecast of ($2.09). SunTrust Banks has a “Buy” rating and a $25.00 price objective on the stock. SunTrust Banks also issued estimates for Epizyme’s FY2020 earnings at ($2.16) EPS, FY2021 earnings at ($1.06) EPS and FY2022 earnings at $0.52 EPS.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.11. The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $0.54 million. The company’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.48) earnings per share.
Shares of NASDAQ:EPZM opened at $10.20 on Thursday. The firm has a market capitalization of $722.83 million, a P/E ratio of -4.68 and a beta of 1.81. Epizyme has a 1 year low of $8.61 and a 1 year high of $21.40.
A number of large investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new stake in Epizyme during the first quarter worth about $111,000. Principal Financial Group Inc. bought a new stake in Epizyme during the first quarter worth about $187,000. Element Capital Management LLC bought a new stake in Epizyme during the first quarter worth about $207,000. BB&T Securities LLC grew its stake in Epizyme by 45.5% during the second quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 5,000 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Epizyme during the first quarter worth about $273,000. 85.06% of the stock is owned by hedge funds and other institutional investors.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Recommended Story: Diversification in Your Portfolio
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.